BRUKINSA Demonstrates Strong 6-Year PFS in Treatment-Naïve CLL Patients
These long-term efficacy data for BRUKINSA in treatment-naïve CLL patients are highly significant, establishing it as a durable and effective foundational therapy.
BRUKINSA demonstrated a 74% 6-year progression-free survival rate in treatment-naïve CLL patients.
BeOne Medicines announced landmark data showing BRUKINSA achieved a 74% 6-year progression-free survival (PFS) rate in patients with treatment-naïve chronic lymphocytic leukemia (CLL). These results, presented at ASH 2025, underscore BRUKINSA's long-term efficacy and durability as a foundational treatment for CLL, reinforcing its position in the market.
These long-term efficacy data for BRUKINSA in treatment-naïve CLL patients are highly significant, establishing it as a durable and effective foundational therapy. This reinforces its value proposition for healthcare providers and patients globally. In APAC, where CLL incidence is notable, these results will influence treatment guidelines and patient selection, potentially leading to wider adoption and improved outcomes.
The strong long-term efficacy of BRUKINSA in treatment-naïve CLL is crucial for APAC markets. CLL is a significant hematological malignancy in the region. These data will support market access, reimbursement discussions, and physician confidence, potentially leading to increased use of BRUKINSA as a first-line treatment for CLL patients across Asia-Pacific.
Where this signal fits in the broader landscape.
BeiGene Announces Q4 and Full Year 2025 Financial Results
BeiGene Announces Fourth Quarter and Full Year 2025 Financial Results
BeOne Medicines Announces Q4 and FY2025 Financial Results
BeiGene's PD-1 Inhibitor Tislelizumab Approved in Japan, Challenging Global Pharma Giants
BeOne Medicines to Announce Q4 and Full Year 2025 Financial Results
https://www.beigene.com/news/brukinsa-delivers-landmark-74-6-year-pfs-in-patients-with-treatment-na-ive-chronic-lymphocytic-leukemia
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
로그인